 | • レポートコード：MRC2-11QY02584 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は抗肥満療法のグローバル市場について調査・分析したレポートです。種類別（中枢作用性抗肥満薬、末梢作用性抗肥満薬）市場規模、用途別（病院用、診療所用、家庭用、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別抗肥満療法の競争状況、市場シェア ・世界の抗肥満療法市場：種類別市場規模 2015年-2020年（中枢作用性抗肥満薬、末梢作用性抗肥満薬） ・世界の抗肥満療法市場：種類別市場規模予測 2021年-2026年（中枢作用性抗肥満薬、末梢作用性抗肥満薬） ・世界の抗肥満療法市場：用途別市場規模 2015年-2020年（病院用、診療所用、家庭用、その他） ・世界の抗肥満療法市場：用途別市場規模予測 2021年-2026年（病院用、診療所用、家庭用、その他） ・北米の抗肥満療法市場分析：米国、カナダ ・ヨーロッパの抗肥満療法市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの抗肥満療法市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の抗肥満療法市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの抗肥満療法市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bristol-Myers Squibb、Eisai Company、FlaxoSithKline plc.、Novo Nordisk、Alizyme、BoehringerIngelheim GmbH、Pfizer、Takeda Pharmaceutical、Rhythm Pharmaceuticals、Shionogi USA、Vivus、Zafgen、Norgine Pharmaceuticals Ltd. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Anti-obesity drugs are the drugs that help in reducing or controlling body mass, either by decreasing the craving or increasing the consumption of calories. Appetite control is achieved through the use of agonists for appetite suppressing pathways.
Geographically, North America captures the largest market share on account of increasing obese population. As per the historical trends, more than one-third of the U.S. population is obese. However, Asia Pacific is anticipated to grow at the fastest rate due to increasing demand for the drugs and awareness about the risk associated with obesity. According to WHO, 13.0% of the population were obese in 2014. In developing countries the rate of childhood obesity is increasing and has been 30.0% higher than that of developed countries.
Market Analysis and Insights: Global Anti-Obesity Therapeutics Market
The global Anti-Obesity Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Anti-Obesity Therapeutics Scope and Market Size
Anti-Obesity Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Obesity Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Anti-Obesity Therapeutics market is segmented into
Centrally Acting Anti-obesity Drugs
Peripherally Acting Anti-obesity Drugs
Segment by Application, the Anti-Obesity Therapeutics market is segmented into
Hospital Use
Clinic Use
Household
Other
Regional and Country-level Analysis
The Anti-Obesity Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Anti-Obesity Therapeutics market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Anti-Obesity Therapeutics Market Share Analysis
Anti-Obesity Therapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Anti-Obesity Therapeutics business, the date to enter into the Anti-Obesity Therapeutics market, Anti-Obesity Therapeutics product introduction, recent developments, etc.
The major vendors covered:
Bristol-Myers Squibb
Eisai Company
FlaxoSithKline plc.
Novo Nordisk
Alizyme
BoehringerIngelheim GmbH
Pfizer
Takeda Pharmaceutical
Rhythm Pharmaceuticals
Shionogi USA
Vivus
Zafgen
Norgine Pharmaceuticals Ltd.
1 Study Coverage
1.1 Anti-Obesity Therapeutics Product Introduction
1.2 Market Segments
1.3 Key Anti-Obesity Therapeutics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Anti-Obesity Therapeutics Market Size Growth Rate by Type
1.4.2 Centrally Acting Anti-obesity Drugs
1.4.3 Peripherally Acting Anti-obesity Drugs
1.5 Market by Application
1.5.1 Global Anti-Obesity Therapeutics Market Size Growth Rate by Application
1.5.2 Hospital Use
1.5.3 Clinic Use
1.5.4 Household
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Anti-Obesity Therapeutics Market Size, Estimates and Forecasts
2.1.1 Global Anti-Obesity Therapeutics Revenue 2015-2026
2.1.2 Global Anti-Obesity Therapeutics Sales 2015-2026
2.2 Global Anti-Obesity Therapeutics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Anti-Obesity Therapeutics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Anti-Obesity Therapeutics Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Anti-Obesity Therapeutics Competitor Landscape by Players
3.1 Anti-Obesity Therapeutics Sales by Manufacturers
3.1.1 Anti-Obesity Therapeutics Sales by Manufacturers (2015-2020)
3.1.2 Anti-Obesity Therapeutics Sales Market Share by Manufacturers (2015-2020)
3.2 Anti-Obesity Therapeutics Revenue by Manufacturers
3.2.1 Anti-Obesity Therapeutics Revenue by Manufacturers (2015-2020)
3.2.2 Anti-Obesity Therapeutics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Anti-Obesity Therapeutics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Anti-Obesity Therapeutics Revenue in 2019
3.2.5 Global Anti-Obesity Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Anti-Obesity Therapeutics Price by Manufacturers
3.4 Anti-Obesity Therapeutics Manufacturing Base Distribution, Product Types
3.4.1 Anti-Obesity Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Anti-Obesity Therapeutics Product Type
3.4.3 Date of International Manufacturers Enter into Anti-Obesity Therapeutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Anti-Obesity Therapeutics Market Size by Type (2015-2020)
4.1.1 Global Anti-Obesity Therapeutics Sales by Type (2015-2020)
4.1.2 Global Anti-Obesity Therapeutics Revenue by Type (2015-2020)
4.1.3 Anti-Obesity Therapeutics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Anti-Obesity Therapeutics Market Size Forecast by Type (2021-2026)
4.2.1 Global Anti-Obesity Therapeutics Sales Forecast by Type (2021-2026)
4.2.2 Global Anti-Obesity Therapeutics Revenue Forecast by Type (2021-2026)
4.2.3 Anti-Obesity Therapeutics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Anti-Obesity Therapeutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Anti-Obesity Therapeutics Market Size by Application (2015-2020)
5.1.1 Global Anti-Obesity Therapeutics Sales by Application (2015-2020)
5.1.2 Global Anti-Obesity Therapeutics Revenue by Application (2015-2020)
5.1.3 Anti-Obesity Therapeutics Price by Application (2015-2020)
5.2 Anti-Obesity Therapeutics Market Size Forecast by Application (2021-2026)
5.2.1 Global Anti-Obesity Therapeutics Sales Forecast by Application (2021-2026)
5.2.2 Global Anti-Obesity Therapeutics Revenue Forecast by Application (2021-2026)
5.2.3 Global Anti-Obesity Therapeutics Price Forecast by Application (2021-2026)
6 North America
6.1 North America Anti-Obesity Therapeutics by Country
6.1.1 North America Anti-Obesity Therapeutics Sales by Country
6.1.2 North America Anti-Obesity Therapeutics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Anti-Obesity Therapeutics Market Facts & Figures by Type
6.3 North America Anti-Obesity Therapeutics Market Facts & Figures by Application
7 Europe
7.1 Europe Anti-Obesity Therapeutics by Country
7.1.1 Europe Anti-Obesity Therapeutics Sales by Country
7.1.2 Europe Anti-Obesity Therapeutics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Anti-Obesity Therapeutics Market Facts & Figures by Type
7.3 Europe Anti-Obesity Therapeutics Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Anti-Obesity Therapeutics by Region
8.1.1 Asia Pacific Anti-Obesity Therapeutics Sales by Region
8.1.2 Asia Pacific Anti-Obesity Therapeutics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Anti-Obesity Therapeutics Market Facts & Figures by Type
8.3 Asia Pacific Anti-Obesity Therapeutics Market Facts & Figures by Application
9 Latin America
9.1 Latin America Anti-Obesity Therapeutics by Country
9.1.1 Latin America Anti-Obesity Therapeutics Sales by Country
9.1.2 Latin America Anti-Obesity Therapeutics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Anti-Obesity Therapeutics Market Facts & Figures by Type
9.3 Central & South America Anti-Obesity Therapeutics Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Anti-Obesity Therapeutics by Country
10.1.1 Middle East and Africa Anti-Obesity Therapeutics Sales by Country
10.1.2 Middle East and Africa Anti-Obesity Therapeutics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Anti-Obesity Therapeutics Market Facts & Figures by Type
10.3 Middle East and Africa Anti-Obesity Therapeutics Market Facts & Figures by Application
11 Company Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Corporation Information
11.1.2 Bristol-Myers Squibb Description and Business Overview
11.1.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol-Myers Squibb Anti-Obesity Therapeutics Products Offered
11.1.5 Bristol-Myers Squibb Related Developments
11.2 Eisai Company
11.2.1 Eisai Company Corporation Information
11.2.2 Eisai Company Description and Business Overview
11.2.3 Eisai Company Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Eisai Company Anti-Obesity Therapeutics Products Offered
11.2.5 Eisai Company Related Developments
11.3 FlaxoSithKline plc.
11.3.1 FlaxoSithKline plc. Corporation Information
11.3.2 FlaxoSithKline plc. Description and Business Overview
11.3.3 FlaxoSithKline plc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 FlaxoSithKline plc. Anti-Obesity Therapeutics Products Offered
11.3.5 FlaxoSithKline plc. Related Developments
11.4 Novo Nordisk
11.4.1 Novo Nordisk Corporation Information
11.4.2 Novo Nordisk Description and Business Overview
11.4.3 Novo Nordisk Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Novo Nordisk Anti-Obesity Therapeutics Products Offered
11.4.5 Novo Nordisk Related Developments
11.5 Alizyme
11.5.1 Alizyme Corporation Information
11.5.2 Alizyme Description and Business Overview
11.5.3 Alizyme Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Alizyme Anti-Obesity Therapeutics Products Offered
11.5.5 Alizyme Related Developments
11.6 BoehringerIngelheim GmbH
11.6.1 BoehringerIngelheim GmbH Corporation Information
11.6.2 BoehringerIngelheim GmbH Description and Business Overview
11.6.3 BoehringerIngelheim GmbH Sales, Revenue and Gross Margin (2015-2020)
11.6.4 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Products Offered
11.6.5 BoehringerIngelheim GmbH Related Developments
11.7 Pfizer
11.7.1 Pfizer Corporation Information
11.7.2 Pfizer Description and Business Overview
11.7.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Pfizer Anti-Obesity Therapeutics Products Offered
11.7.5 Pfizer Related Developments
11.8 Takeda Pharmaceutical
11.8.1 Takeda Pharmaceutical Corporation Information
11.8.2 Takeda Pharmaceutical Description and Business Overview
11.8.3 Takeda Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Takeda Pharmaceutical Anti-Obesity Therapeutics Products Offered
11.8.5 Takeda Pharmaceutical Related Developments
11.9 Rhythm Pharmaceuticals
11.9.1 Rhythm Pharmaceuticals Corporation Information
11.9.2 Rhythm Pharmaceuticals Description and Business Overview
11.9.3 Rhythm Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Products Offered
11.9.5 Rhythm Pharmaceuticals Related Developments
11.10 Shionogi USA
11.10.1 Shionogi USA Corporation Information
11.10.2 Shionogi USA Description and Business Overview
11.10.3 Shionogi USA Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Shionogi USA Anti-Obesity Therapeutics Products Offered
11.10.5 Shionogi USA Related Developments
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Corporation Information
11.1.2 Bristol-Myers Squibb Description and Business Overview
11.1.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol-Myers Squibb Anti-Obesity Therapeutics Products Offered
11.1.5 Bristol-Myers Squibb Related Developments
11.12 Zafgen
11.12.1 Zafgen Corporation Information
11.12.2 Zafgen Description and Business Overview
11.12.3 Zafgen Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Zafgen Products Offered
11.12.5 Zafgen Related Developments
11.13 Norgine Pharmaceuticals Ltd.
11.13.1 Norgine Pharmaceuticals Ltd. Corporation Information
11.13.2 Norgine Pharmaceuticals Ltd. Description and Business Overview
11.13.3 Norgine Pharmaceuticals Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Norgine Pharmaceuticals Ltd. Products Offered
11.13.5 Norgine Pharmaceuticals Ltd. Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Anti-Obesity Therapeutics Market Estimates and Projections by Region
12.1.1 Global Anti-Obesity Therapeutics Sales Forecast by Regions 2021-2026
12.1.2 Global Anti-Obesity Therapeutics Revenue Forecast by Regions 2021-2026
12.2 North America Anti-Obesity Therapeutics Market Size Forecast (2021-2026)
12.2.1 North America: Anti-Obesity Therapeutics Sales Forecast (2021-2026)
12.2.2 North America: Anti-Obesity Therapeutics Revenue Forecast (2021-2026)
12.2.3 North America: Anti-Obesity Therapeutics Market Size Forecast by Country (2021-2026)
12.3 Europe Anti-Obesity Therapeutics Market Size Forecast (2021-2026)
12.3.1 Europe: Anti-Obesity Therapeutics Sales Forecast (2021-2026)
12.3.2 Europe: Anti-Obesity Therapeutics Revenue Forecast (2021-2026)
12.3.3 Europe: Anti-Obesity Therapeutics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Anti-Obesity Therapeutics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Anti-Obesity Therapeutics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Anti-Obesity Therapeutics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Anti-Obesity Therapeutics Market Size Forecast by Region (2021-2026)
12.5 Latin America Anti-Obesity Therapeutics Market Size Forecast (2021-2026)
12.5.1 Latin America: Anti-Obesity Therapeutics Sales Forecast (2021-2026)
12.5.2 Latin America: Anti-Obesity Therapeutics Revenue Forecast (2021-2026)
12.5.3 Latin America: Anti-Obesity Therapeutics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Anti-Obesity Therapeutics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Anti-Obesity Therapeutics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Anti-Obesity Therapeutics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Anti-Obesity Therapeutics Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Anti-Obesity Therapeutics Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Anti-Obesity Therapeutics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Anti-Obesity Therapeutics Market Segments
Table 2. Ranking of Global Top Anti-Obesity Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Anti-Obesity Therapeutics Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Centrally Acting Anti-obesity Drugs
Table 5. Major Manufacturers of Peripherally Acting Anti-obesity Drugs
Table 6. Global Anti-Obesity Therapeutics Market Size Growth Rate by Application 2020-2026 (K Units)
Table 7. Global Anti-Obesity Therapeutics Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 8. Global Anti-Obesity Therapeutics Sales by Regions 2015-2020 (K Units)
Table 9. Global Anti-Obesity Therapeutics Sales Market Share by Regions (2015-2020)
Table 10. Global Anti-Obesity Therapeutics Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global Anti-Obesity Therapeutics Sales by Manufacturers (2015-2020) (K Units)
Table 12. Global Anti-Obesity Therapeutics Sales Share by Manufacturers (2015-2020)
Table 13. Global Anti-Obesity Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global Anti-Obesity Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Obesity Therapeutics as of 2019)
Table 15. Anti-Obesity Therapeutics Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. Anti-Obesity Therapeutics Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers Anti-Obesity Therapeutics Price (2015-2020) (USD/Unit)
Table 18. Anti-Obesity Therapeutics Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Anti-Obesity Therapeutics Product Type
Table 20. Date of International Manufacturers Enter into Anti-Obesity Therapeutics Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Anti-Obesity Therapeutics Sales by Type (2015-2020) (K Units)
Table 23. Global Anti-Obesity Therapeutics Sales Share by Type (2015-2020)
Table 24. Global Anti-Obesity Therapeutics Revenue by Type (2015-2020) (US$ Million)
Table 25. Global Anti-Obesity Therapeutics Revenue Share by Type (2015-2020)
Table 26. Anti-Obesity Therapeutics Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 27. Global Anti-Obesity Therapeutics Sales by Application (2015-2020) (K Units)
Table 28. Global Anti-Obesity Therapeutics Sales Share by Application (2015-2020)
Table 29. North America Anti-Obesity Therapeutics Sales by Country (2015-2020) (K Units)
Table 30. North America Anti-Obesity Therapeutics Sales Market Share by Country (2015-2020)
Table 31. North America Anti-Obesity Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 32. North America Anti-Obesity Therapeutics Revenue Market Share by Country (2015-2020)
Table 33. North America Anti-Obesity Therapeutics Sales by Type (2015-2020) (K Units)
Table 34. North America Anti-Obesity Therapeutics Sales Market Share by Type (2015-2020)
Table 35. North America Anti-Obesity Therapeutics Sales by Application (2015-2020) (K Units)
Table 36. North America Anti-Obesity Therapeutics Sales Market Share by Application (2015-2020)
Table 37. Europe Anti-Obesity Therapeutics Sales by Country (2015-2020) (K Units)
Table 38. Europe Anti-Obesity Therapeutics Sales Market Share by Country (2015-2020)
Table 39. Europe Anti-Obesity Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe Anti-Obesity Therapeutics Revenue Market Share by Country (2015-2020)
Table 41. Europe Anti-Obesity Therapeutics Sales by Type (2015-2020) (K Units)
Table 42. Europe Anti-Obesity Therapeutics Sales Market Share by Type (2015-2020)
Table 43. Europe Anti-Obesity Therapeutics Sales by Application (2015-2020) (K Units)
Table 44. Europe Anti-Obesity Therapeutics Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific Anti-Obesity Therapeutics Sales by Region (2015-2020) (K Units)
Table 46. Asia Pacific Anti-Obesity Therapeutics Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific Anti-Obesity Therapeutics Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific Anti-Obesity Therapeutics Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific Anti-Obesity Therapeutics Sales by Type (2015-2020) (K Units)
Table 50. Asia Pacific Anti-Obesity Therapeutics Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific Anti-Obesity Therapeutics Sales by Application (2015-2020) (K Units)
Table 52. Asia Pacific Anti-Obesity Therapeutics Sales Market Share by Application (2015-2020)
Table 53. Latin America Anti-Obesity Therapeutics Sales by Country (2015-2020) (K Units)
Table 54. Latin America Anti-Obesity Therapeutics Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa Anti-Obesity Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America Anti-Obesity Therapeutics Revenue Market Share by Country (2015-2020)
Table 57. Latin America Anti-Obesity Therapeutics Sales by Type (2015-2020) (K Units)
Table 58. Latin America Anti-Obesity Therapeutics Sales Market Share by Type (2015-2020)
Table 59. Latin America Anti-Obesity Therapeutics Sales by Application (2015-2020) (K Units)
Table 60. Latin America Anti-Obesity Therapeutics Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa Anti-Obesity Therapeutics Sales by Country (2015-2020) (K Units)
Table 62. Middle East and Africa Anti-Obesity Therapeutics Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa Anti-Obesity Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa Anti-Obesity Therapeutics Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa Anti-Obesity Therapeutics Sales by Type (2015-2020) (K Units)
Table 66. Middle East and Africa Anti-Obesity Therapeutics Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa Anti-Obesity Therapeutics Sales by Application (2015-2020) (K Units)
Table 68. Middle East and Africa Anti-Obesity Therapeutics Sales Market Share by Application (2015-2020)
Table 69. Bristol-Myers Squibb Corporation Information
Table 70. Bristol-Myers Squibb Description and Major Businesses
Table 71. Bristol-Myers Squibb Anti-Obesity Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 72. Bristol-Myers Squibb Product
Table 73. Bristol-Myers Squibb Recent Development
Table 74. Eisai Company Corporation Information
Table 75. Eisai Company Description and Major Businesses
Table 76. Eisai Company Anti-Obesity Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 77. Eisai Company Product
Table 78. Eisai Company Recent Development
Table 79. FlaxoSithKline plc. Corporation Information
Table 80. FlaxoSithKline plc. Description and Major Businesses
Table 81. FlaxoSithKline plc. Anti-Obesity Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 82. FlaxoSithKline plc. Product
Table 83. FlaxoSithKline plc. Recent Development
Table 84. Novo Nordisk Corporation Information
Table 85. Novo Nordisk Description and Major Businesses
Table 86. Novo Nordisk Anti-Obesity Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 87. Novo Nordisk Product
Table 88. Novo Nordisk Recent Development
Table 89. Alizyme Corporation Information
Table 90. Alizyme Description and Major Businesses
Table 91. Alizyme Anti-Obesity Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 92. Alizyme Product
Table 93. Alizyme Recent Development
Table 94. BoehringerIngelheim GmbH Corporation Information
Table 95. BoehringerIngelheim GmbH Description and Major Businesses
Table 96. BoehringerIngelheim GmbH Anti-Obesity Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 97. BoehringerIngelheim GmbH Product
Table 98. BoehringerIngelheim GmbH Recent Development
Table 99. Pfizer Corporation Information
Table 100. Pfizer Description and Major Businesses
Table 101. Pfizer Anti-Obesity Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 102. Pfizer Product
Table 103. Pfizer Recent Development
Table 104. Takeda Pharmaceutical Corporation Information
Table 105. Takeda Pharmaceutical Description and Major Businesses
Table 106. Takeda Pharmaceutical Anti-Obesity Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 107. Takeda Pharmaceutical Product
Table 108. Takeda Pharmaceutical Recent Development
Table 109. Rhythm Pharmaceuticals Corporation Information
Table 110. Rhythm Pharmaceuticals Description and Major Businesses
Table 111. Rhythm Pharmaceuticals Anti-Obesity Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 112. Rhythm Pharmaceuticals Product
Table 113. Rhythm Pharmaceuticals Recent Development
Table 114. Shionogi USA Corporation Information
Table 115. Shionogi USA Description and Major Businesses
Table 116. Shionogi USA Anti-Obesity Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 117. Shionogi USA Product
Table 118. Shionogi USA Recent Development
Table 119. Vivus Corporation Information
Table 120. Vivus Description and Major Businesses
Table 121. Vivus Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 122. Vivus Product
Table 123. Vivus Recent Development
Table 124. Zafgen Corporation Information
Table 125. Zafgen Description and Major Businesses
Table 126. Zafgen Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 127. Zafgen Product
Table 128. Zafgen Recent Development
Table 129. Norgine Pharmaceuticals Ltd. Corporation Information
Table 130. Norgine Pharmaceuticals Ltd. Description and Major Businesses
Table 131. Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 132. Norgine Pharmaceuticals Ltd. Product
Table 133. Norgine Pharmaceuticals Ltd. Recent Development
Table 134. Global Anti-Obesity Therapeutics Sales Forecast by Regions (2021-2026) (K Units)
Table 135. Global Anti-Obesity Therapeutics Sales Market Share Forecast by Regions (2021-2026)
Table 136. Global Anti-Obesity Therapeutics Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 137. Global Anti-Obesity Therapeutics Revenue Market Share Forecast by Regions (2021-2026)
Table 138. North America: Anti-Obesity Therapeutics Sales Forecast by Country (2021-2026) (K Units)
Table 139. North America: Anti-Obesity Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 140. Europe: Anti-Obesity Therapeutics Sales Forecast by Country (2021-2026) (K Units)
Table 141. Europe: Anti-Obesity Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 142. Asia Pacific: Anti-Obesity Therapeutics Sales Forecast by Region (2021-2026) (K Units)
Table 143. Asia Pacific: Anti-Obesity Therapeutics Revenue Forecast by Region (2021-2026) (US$ Million)
Table 144. Latin America: Anti-Obesity Therapeutics Sales Forecast by Country (2021-2026) (K Units)
Table 145. Latin America: Anti-Obesity Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 146. Middle East and Africa: Anti-Obesity Therapeutics Sales Forecast by Country (2021-2026) (K Units)
Table 147. Middle East and Africa: Anti-Obesity Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 148. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 149. Key Challenges
Table 150. Market Risks
Table 151. Main Points Interviewed from Key Anti-Obesity Therapeutics Players
Table 152. Anti-Obesity Therapeutics Customers List
Table 153. Anti-Obesity Therapeutics Distributors List
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Obesity Therapeutics Product Picture
Figure 2. Global Anti-Obesity Therapeutics Sales Market Share by Type in 2020 & 2026
Figure 3. Centrally Acting Anti-obesity Drugs Product Picture
Figure 4. Peripherally Acting Anti-obesity Drugs Product Picture
Figure 5. Global Anti-Obesity Therapeutics Sales Market Share by Application in 2020 & 2026
Figure 6. Hospital Use
Figure 7. Clinic Use
Figure 8. Household
Figure 9. Other
Figure 10. Anti-Obesity Therapeutics Report Years Considered
Figure 11. Global Anti-Obesity Therapeutics Market Size 2015-2026 (US$ Million)
Figure 12. Global Anti-Obesity Therapeutics Sales 2015-2026 (K Units)
Figure 13. Global Anti-Obesity Therapeutics Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Anti-Obesity Therapeutics Sales Market Share by Region (2015-2020)
Figure 15. Global Anti-Obesity Therapeutics Sales Market Share by Region in 2019
Figure 16. Global Anti-Obesity Therapeutics Revenue Market Share by Region (2015-2020)
Figure 17. Global Anti-Obesity Therapeutics Revenue Market Share by Region in 2019
Figure 18. Global Anti-Obesity Therapeutics Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Anti-Obesity Therapeutics Revenue in 2019
Figure 20. Anti-Obesity Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Anti-Obesity Therapeutics Sales Market Share by Type (2015-2020)
Figure 22. Global Anti-Obesity Therapeutics Sales Market Share by Type in 2019
Figure 23. Global Anti-Obesity Therapeutics Revenue Market Share by Type (2015-2020)
Figure 24. Global Anti-Obesity Therapeutics Revenue Market Share by Type in 2019
Figure 25. Global Anti-Obesity Therapeutics Market Share by Price Range (2015-2020)
Figure 26. Global Anti-Obesity Therapeutics Sales Market Share by Application (2015-2020)
Figure 27. Global Anti-Obesity Therapeutics Sales Market Share by Application in 2019
Figure 28. Global Anti-Obesity Therapeutics Revenue Market Share by Application (2015-2020)
Figure 29. Global Anti-Obesity Therapeutics Revenue Market Share by Application in 2019
Figure 30. North America Anti-Obesity Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 31. North America Anti-Obesity Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Anti-Obesity Therapeutics Sales Market Share by Country in 2019
Figure 33. North America Anti-Obesity Therapeutics Revenue Market Share by Country in 2019
Figure 34. U.S. Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 35. U.S. Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 37. Canada Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Anti-Obesity Therapeutics Market Share by Type in 2019
Figure 39. North America Anti-Obesity Therapeutics Market Share by Application in 2019
Figure 40. Europe Anti-Obesity Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 41. Europe Anti-Obesity Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Anti-Obesity Therapeutics Sales Market Share by Country in 2019
Figure 43. Europe Anti-Obesity Therapeutics Revenue Market Share by Country in 2019
Figure 44. Germany Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 45. Germany Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 47. France Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 49. U.K. Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 51. Italy Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 53. Russia Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Anti-Obesity Therapeutics Market Share by Type in 2019
Figure 55. Europe Anti-Obesity Therapeutics Market Share by Application in 2019
Figure 56. Asia Pacific Anti-Obesity Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 57. Asia Pacific Anti-Obesity Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Anti-Obesity Therapeutics Sales Market Share by Region in 2019
Figure 59. Asia Pacific Anti-Obesity Therapeutics Revenue Market Share by Region in 2019
Figure 60. China Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 61. China Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 63. Japan Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 65. South Korea Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 67. India Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 69. Australia Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 71. Taiwan Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 73. Indonesia Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 75. Thailand Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 77. Malaysia Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 79. Philippines Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 81. Vietnam Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Anti-Obesity Therapeutics Market Share by Type in 2019
Figure 83. Asia Pacific Anti-Obesity Therapeutics Market Share by Application in 2019
Figure 84. Latin America Anti-Obesity Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 85. Latin America Anti-Obesity Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Anti-Obesity Therapeutics Sales Market Share by Country in 2019
Figure 87. Latin America Anti-Obesity Therapeutics Revenue Market Share by Country in 2019
Figure 88. Mexico Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 89. Mexico Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 91. Brazil Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 93. Argentina Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Anti-Obesity Therapeutics Market Share by Type in 2019
Figure 95. Latin America Anti-Obesity Therapeutics Market Share by Application in 2019
Figure 96. Middle East and Africa Anti-Obesity Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 97. Middle East and Africa Anti-Obesity Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Anti-Obesity Therapeutics Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Anti-Obesity Therapeutics Revenue Market Share by Country in 2019
Figure 100. Turkey Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 101. Turkey Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 103. Saudi Arabia Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Anti-Obesity Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 105. U.A.E Anti-Obesity Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Anti-Obesity Therapeutics Market Share by Type in 2019
Figure 107. Middle East and Africa Anti-Obesity Therapeutics Market Share by Application in 2019
Figure 108. North America Anti-Obesity Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 109. North America Anti-Obesity Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Anti-Obesity Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. Europe Anti-Obesity Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Anti-Obesity Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Asia Pacific Anti-Obesity Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Anti-Obesity Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Latin America Anti-Obesity Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Anti-Obesity Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Middle East and Africa Anti-Obesity Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed
抗肥満薬の世界市場（～2026年） Anti-obesity drugs are pharmacological agents that reduce or control weight. These drugs alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories. The main treatment modalities for overweight and obese individuals remain diet…- 抗肥満薬（抗肥満薬）の世界市場（～2026年） Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control weight. These medications alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories. Market Analysis and Insights: Global Ant…
- 抗肥満処方の世界市場（～2026年） Obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory …
- 肥満管理の世界市場（～2026年） Lifestyle diseases such as diabetes and other chronic ailments are the main cause of obesity around the world. Improved healthcare and medical facilities have led to an increase in the life expectancy of people, which is the primary reason for the large geriatric population seen in the developed wor…
- 肥満治療の世界市場（～2026年） Market Analysis and Insights: Global Obesity Treatment Market The global Obesity Treatment market size is projected to reach US$ 5620.7 million by 2026, from US$ 4912 million in 2020, at a CAGR of 13.4%% during 2021-2026. Global Obesity Treatment Scope and Market Size Obesity Treatment market is seg…